Table 1 Baseline characteristics of the study participants
Characteristic | Total (n = 1819) | high-grade CIN | high-grade VaIN | P-value |
|---|---|---|---|---|
(n = 1665) | (n = 154) | |||
Age, Mean ± SD | 37.2 ± 10.3 | 36.7 ± 10.0 | 42.1 ± 12.4 | < 0.001 |
Age, year,n (%) | < 0.001 | |||
<25 | 111 ( 6.1) | 104 (6.2) | 7 (4.5) | |
25–29 | 345 (19.0) | 326 (19.6) | 19 (12.3) | |
30–39 | 763 (41.9) | 714 (42.9) | 49 (31.8) | |
40–49 | 354 (19.5) | 323 (19.4) | 31 (20.1) | |
50–59 | 175 ( 9.6) | 140 (8.4) | 35 (22.7) | |
60–65 | 50 ( 2.7) | 41 (2.5) | 9 (5.8) | |
>65 | 21 ( 1.2) | 17 (1) | 4 (2.6) | |
Sexual life year, Mean ± SD | 16.1 ± 9.8 | 15.7 ± 9.5 | 20.7 ± 11.8 | < 0.001 |
Sexual life year, n (%) | 0.01 | |||
≤ 1 | 26 ( 1.4) | 24 (1.4) | 2 (1.3) | |
2–3 | 59 ( 3.2) | 53 (3.2) | 6 (3.9) | |
4–10 | 499 (27.4) | 473 (28.4) | 26 (16.9) | |
>10 | 1208 (66.4) | 1093 (65.6) | 115 (74.7) | |
NA | 27 ( 1.5) | 22 (1.3) | 5 (3.2) | |
First sexual life age, Mean ± SD | 21.1 ± 2.9 | 21.1 ± 2.9 | 21.7 ± 3.0 | 0.02 |
Sex mate number, Mean ± SD | 2.1 ± 1.6 | 2.1 ± 1.6 | 1.9 ± 1.7 | 0.113 |
Menopausal status, n (%) | < 0.001 | |||
NO | 1654 (90.9) | 1540 (92.5) | 114 (74) | |
YES | 165 ( 9.1) | 125 (7.5) | 40 (26) | |
Contraceptive, n (%) | 0.079 | |||
NO | 584 (32.1) | 522 (31.4) | 62 (40.3) | |
YES | 1233 (67.8) | 1141 (68.5) | 92 (59.7) | |
Gravidity, Mean ± SD | 2.6 ± 1.9 | 2.6 ± 1.8 | 3.1 ± 2.2 | < 0.001 |
Parity, Mean ± SD | 1.4 ± 1.1 | 1.4 ± 1.1 | 1.8 ± 1.3 | < 0.001 |
Family history of cancer, n (%) | 212 (11.8) | 186 (11.3) | 26 (17.1) | 0.032 |
Clinical manifestation, n (%) | < 0.001 | |||
NO | 1337 (73.7) | 1205 (72.5) | 132 (85.7) | |
YES | 478 (26.3) | 456 (27.5) | 22 (14.3) | |
Abnormal eukorrhea, n (%) | 257 (14.1) | 247 (14.8) | 10 (6.5) | 0.004 |
Abnormal bleeding, n (%) | 247 (13.6) | 234 (14.1) | 13 (8.4) | 0.052 |
Prior cervical treatment, n (%) | < 0.001 | |||
NO | 1645 (90.4) | 1554 (93.3) | 91 (59.1) | |
YES | 174 ( 9.6) | 111 (6.7) | 63 (40.9) | |
TCT,n (%) | 0.006 | |||
NILM | 566 (31.1) | 508 (30.5) | 58 (37.7) | |
ASC-US/AGC | 359 (19.7) | 337 (20.2) | 22 (14.3) | |
LSIL | 419 (23.0) | 370 (22.2) | 49 (31.8) | |
ASC-H | 189 (10.4) | 179 (10.8) | 10 (6.5) | |
HSIL | 277 (15.2) | 262 (15.7) | 15 (9.7) | |
AIS/SCC | 9 ( 0.5) | 9 (0.5) | 0 (0) | |
HPV,n (%) | 0.619 | |||
HPV(-) | 52 ( 2.9) | 49 (2.9) | 3 (1.9) | |
HPV(+) | 1767 (97.1) | 1616 (97.1) | 151 (98.1) | |
Single HPV infection, n (%) | 1161 (63.8) | 1071 (64.3) | 90 (58.4) | 0.146 |
Multiple HPV infection, n (%) | 607 (33.4) | 546 (32.8) | 61 (39.6) | 0.086 |
Subtotal hysterectomy, n (%) | 28 ( 1.5) | 1 (0.1) | 27 (17.5) | < 0.001 |
Prior CIN treatment,n (%) | < 0.001 | |||
NO | 1716 (94.3) | 1601 (96.2) | 115 (74.7) | |
YES | 103 ( 5.7) | 64 (3.8) | 39 (25.3) | |
Prior CC treatment,n (%) | < 0.001 | |||
NO | 1809 (99.5) | 1665 (100) | 144 (93.5) | |
YES | 10 ( 0.5) | 0 (0) | 10 (6.5) |